series-c-plus
Stage
About
Apollomics, Inc. is a biotechnology company that discovers and develops oncology therapies, emphasizing combination treatments that harness the immune system and target specific molecular pathways. Its clinical-stage pipeline includes programs such as vebreltinib (APL-101), APL-102 and APL-501.
Explore Apollomics, Inc.'s full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.